Yanqing Li
13
1
1
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
50%
1 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial
Role: lead
Pinaverium Bromide Preventing Post Extracorporeal Shock Wave Lithotripsy Pancreatitis and Painful (PBPEP)
Role: lead
Comparison of Two Dual Therapies in the First-line Treatment of Helicobacter Pylori Infection （SHARE2301）
Role: lead
Different Endoscopic Gastric Cancer Risk Assessments
Role: lead
Bowel Preparation May Lead to a Higher Feasibility of Intestinal Infection
Role: lead
Application of AI in Polypectomy
Role: lead
Quality Control of Esophagogastroduodenoscopy Using Real-time EGD Auxiliary System
Role: lead
A Questionnaire for Endoscopic Prediction Improvement of Gastrointestinal Cancer
Role: lead
Medical Consortium for Screening Upper Gastrointestinal Cancers With Magnetically Controlled Capsule Gastroscopy
Role: lead
Outcomes of A Novel Treatment Decision of Patients With Esophageal and Head and Neck Carcinoma Synchronously
Role: lead
Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment
Role: lead
Efficacy of Segmental Examination Twice of the Proximal Colon on Adenoma Detection
Role: lead
Detection of Colorectal Adenoma by Optical Enhancement Technology vs. High-Definition Colonoscopy
Role: lead
All 13 trials loaded